-
Mashup Score: 0Pembrolizumab sBLA Resubmitted to FDA With New Dosing Frequency - 4 year(s) ago
“The oncology community is rapidly adapting cancer care during the COVID-19 pandemic in order to minimize exposure and keep cancer patients as safe as possible. Now more than ever, we believe it is critical to pursue a six-week dosing schedule for Keytruda.”
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0A Look Back at the FDA News from June 2020 - 4 year(s) ago
Here is a look back at the FDA happenings from the month of June 2020.
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out all the FDA happenings from the month of June, including yesterday's approval of avelumab. What FDA news did you find most exciting last month? https://t.co/QzTf3Uuuqe #blcsm #cancercare
-
-
Mashup Score: 0
The addition of trastuzumab to chemotherapy in patients with uterine serous carcinoma had superior outcome compared with chemotherapy alone.
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The addition of trastuzumab to chemotherapy in patients with uterine serous carcinoma had superior outcome compared with chemotherapy alone. https://t.co/KXS2qPhFBs
-
-
Mashup Score: 1Updated Guidelines Focus on Advanced Prostate Cancer - 4 year(s) ago
“Men with advanced prostate cancer have exhausted local therapies and are now moving on to systemic options.”
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @TDTM2V: Updated Guidelines Focus on Advanced #Prostate #Cancer https://t.co/HcuYQXDlls via @targetedonc
-
-
Mashup Score: 1Investigators Employ a Range of Novel and Established Systemic Therapies for Advanced Glioblastoma - 4 year(s) ago
Treatment of glioblastoma has seen few advancements since the approval of temozolomide plus radiotherapy in 2005 for newly diagnosed disease. Recently, promising clinical data have reinvigorated hope for novel therapies in this tumor type.
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @TiborKiss12: Investigators Employ a Range of Novel and Established Systemic Therapies for Advanced Glioblastoma https://t.co/rpYzIQnfKj…
-
-
Mashup Score: 1Tisotumab Induces Clinically Meaningful, Durable Responses in Recurrent Metastatic Cervical Cancer - 4 year(s) ago
“Available therapies upon progression after first-line chemotherapy in recurrent or metastatic cervical cancer are limited, and there is a significant unmet need for new treatment options.”
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @TDTM2V: #Tisotumab Induces #Clinically Meaningful, Durable Responses in Recurrent #Metastatic #Cervical #Cancer https://t.co/n8hwv1aa8S…
-
-
Mashup Score: 0Filling the BCG Shortage Hole for Patients With NMIBC - 4 year(s) ago
A panel discussion during the American Urological Association’s (AUA) Virtual Experience highlighted ways to treat patients with non–muscle invasive bladder cancer (NMIBC) in the face of a shortage of standard-of-care Bacillus Calmette-Guerin (BCG) treatment.1The panel discussion was moderated by Seth P. Lerner, MD, and the panelists included Stephen A. Boorjian, MD; Ashish M. Kamat, MD, MBBS;…
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A recent panel discussion highlighted ways to treat patients with non–muscle invasive bladder cancer in the face of a shortage of standard-of-care Bacillus Calmette-Guerin treatment. https://t.co/gPRI3vryVu #blcsm
-
-
Mashup Score: 1
The FDA approved avelumab as a frontline maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma who have not progressed with frontline platinum-based chemotherapy.
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BREAKING: The FDA approved avelumab as a frontline maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma who have not progressed with frontline platinum-based chemotherapy. https://t.co/1mpcik8WY2 #blcsm
-
-
Mashup Score: 0Updated Guidelines Focus on Advanced Prostate Cancer - 4 year(s) ago
“Men with advanced prostate cancer have exhausted local therapies and are now moving on to systemic options.”
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New guidelines focus on men withadvanced stage disease and now include new treatments, including the use of PARP inhibitors in the metastatic castration-resistant setting. https://t.co/2dqlSjBpUL #pcsm
-
-
Mashup Score: 0Graft-Versus-Host Disease - 4 year(s) ago
Experts in stem cell transplantation review the background of graft-versus-host disease and discuss 3 clinical cases and individualized treatment approaches.
Source: targetedoncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Experts in stem cell transplantation review the background of graft-versus-host disease and discuss 3 clinical cases and individualized treatment approaches. https://t.co/cLAaJGxe87 #GVHD
-
A supplemental Biologics License Application for pembrolizumab has been resubmitted to the FDA to update the dosing frequency to include a 400 mg dose administered via infusion over 30 minutes, every 6 weeks. https://t.co/Kp7co3F8VK #pembrolizumab